| Methods |
RCT
Assessor blinded
1996‐2001 |
| Participants |
Number: 251 patients
Age: med 55, range: 15‐84 |
| Interventions |
cefepime 2grX3
versus
imipenem 500mgX4
In addition, glycopeptides added to 25% and aminoglycosides to 6% of patients (in both study arms). |
| Outcomes |
Overall mortality ‐ at 30 days following end of treatment
Clinical and microbiological failure
Superinfection
Adverse events |
| Notes |
USA |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Low risk |
Randomisation performed by a computer generated number scheme |
| Allocation concealment? |
Low risk |
No description, but previous trials in the center were conducted using the pharmacy as the center of randomization and allocation was disclosed only after patients' entered the trial |
| Blinding?
All outcomes |
High risk |
Randomization was done in an evaluator‐blind fashion. The treatment assignments remained unknown to the investigators in charge of determining eligibility, establishing infectious diagnosis, and evaluating outcome and adverse events throughout the study |
| Incomplete outcome data addressed?
All‐cause mortality |
Low risk |
|
| Incomplete outcome data addressed?
Treatment failure |
Low risk |
|
| Free of other bias? |
Low risk |
|
